Genotype-matched Newcastle disease virus vaccine confers improved protection against genotype XII challenge: The importance of cytoplasmic tails in viral replication and vaccine design
R. Izquierdo-Lara, A. Chumbe, K. Calderon, M. Fernandez-Diaz, V. N. Vakharia
Abstract
Although typical Newcastle disease virus (NDV) vaccines can prevent mortality, they are not effective preventing viral shedding. To overcome this, genotype-matched vaccines have been proposed. To date, this approach has never been tested against genotype XII strains. In this study, we generated and assessed the protection against genotype XII challenge of two chimeric NDV vaccine strains (rLS1-XII-1 and rLS1-XII-2). The rLS1-XII-1 virus has the complete fusion protein (F) and the hemmaglutinin-neuraminidase (HN) open reading frames replaced with those from genotype XII strain NDV/peacock/Peru/2011 (PP2011) in a recombinant LaSota (rLS1) backbone. For rLS1-XII-2 cytoplasmic tails of F and HN proteins were restored to those of rLS1. In vitro studies showed that rLS1-XII-2 and the parental rLS1 strains replicate at higher efficiencies than rLS1-XII-1. In the first vaccine/challenge experiment, SPF chickens vaccinated with rLS1-XII-1 virus showed only 71.3% protection, whereas, rLS1 and rLS1-XII-2 vaccinated chickens were fully protected. In a second experiment, both rLS1-XII-2 and the commercial vaccine strain LaSota induced 100% protection. However, rLS1-XII-2 virus significantly reduced viral shedding, both in the number of shedding birds and in quantity of shed virus. In conclusion, we have developed a vaccine candidate capable of fully protecting chickens against genotype XII challenges. Furthermore, we have shown the importance of cytoplasmic tails in virus replication and vaccine competence.
02 /Specification & Classification
Click any tag to browse matching papersReproducibility ledger
Nobody has reported trying to reproduce this paper yet. Did you replicate an experiment or run the code? Your report saves the next lab a week.
Sign in to file a reproducibility report.
Related papers
- Development and pre-clinical evaluation of Newcastle disease virus-vectored SARS-CoV-2 intranasal vaccine candidate
M. Fernandez-Diaz, K. Calderon, … Salguedo-Bohorqu·bioRxiv·Mar 7, 2021
- Presence of Newcastle Disease in Vaccinated Indigenous Chicken from Farms in Selected Regions in Kenya- a Cross Sectional Study
Auleria Ajiambo Apopo, Jane M. Ngaira, … Leonard O. Ateya·bioRxiv·Jul 20, 2020
- Effects of Combined Viral and Bacterial Vaccine on Production Performance in Broiler Chickens
- The expression of hemagglutinin by a recombinant Newcastle disease virus causes structural changes and alters innate immune sensing
F. Ingrao, V. Duchatel, … B. Lambrecht·bioRxiv·Feb 19, 2020
- Newcastle disease virus (NDV) expressing the spike protein of SARS-CoV-2 as vaccine candidate
W. Sun, S. R. Leist, … P. Palese·bioRxiv·Jul 26, 2020
- A Newcastle disease virus (NDV) expressing membrane-anchored spike as a cost-effective inactivated SARS-CoV-2 vaccine
W. Sun, S. McCroskery, … P. Palese·bioRxiv·Jul 30, 2020